Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015;11(3):501-10.
doi: 10.2217/fon.14.270.

The use of novel agents in multiple myeloma patients with hepatic impairment

Lindsay C Stansfield  1 , Wilson I Gonsalves, Francis K Buadi
Affiliations

The use of novel agents in multiple myeloma patients with hepatic impairment

Lindsay C Stansfield et al. Future Oncol. 2015.

Abstract

Novel drugs such as immunomodulators and proteasome inhibitors have improved the survival of patients with multiple myeloma. Like all therapeutic agents, appropriate dosing based on metabolism and clearance is important to maintain efficacy while avoiding toxicity. Hepatic impairment (HI) in multiple myeloma patients is rare but well described either due to disease or therapy-related factors. However, limited data are available on the appropriate use and dosing of the novel agent therapeutics in myeloma patients with HI. Furthermore, data on HI secondary to the novel agent toxicity are also sparse. This systematic review highlights the evidence on the use of novel agents like thalidomide, lenalidomide, pomalidomide, bortezomib and carfilzomib in patients with HI as well as their associated hepatic toxicities.

Keywords: hepatic impairment; myeloma; novel agents.

PubMed Disclaimer

References

    1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. - PubMed
    1. Kumar SK, Raj SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–2520. This paper demonstrates the importance of novel agents in the. field of myeloma and how it has improved overall survival. - PMC - PubMed
    1. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28(5):1122–1128. - PMC - PubMed
    1. Gonsalves WI, Raj SV, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia: a population based analysis. Blood. 2014;124(6):907–912. - PMC - PubMed
    1. Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) Blood. 2011;118(17):4519–4529. This is a state of the art paper describing the use of novel agents in a personalized fashion based on patient age and comorbidities. - PubMed

Publication types

MeSH terms